Researchers sought to determine the recommended phase 2 dose, safety, and efficacy of pirtobrutinib in patients with B-cell malignancies.
More than two-thirds of patients studied did not undergo biomarker testing.
Increasing karyotypic complexity was an independent predictor of shorter progression-free and overall survival.
For patients with low- or intermediate-risk disease, the risk of dying from CLL progression was similar to the risk of dying from CLL-related complications or from causes unrelated to CLL.
Undetectable MRD was not associated with significantly better PFS at any time point.
Researchers are evaluating the safety and efficacy of acalabrutinib in 3 cohorts.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
Quality of life outcomes were generally the same from baseline through follow-up.
A chemoimmunotherapy regimen with only 3 cycles of chemotherapy was found to be efficacious in a phase 2 trial that sought to reduce treatment-related MDS/AML in patients with CLL.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
At 4 years, there was no significant difference in overall survival.
Efficacy outcomes were similar between the treatment arms.
Experts outline treatment options for patients with venetoclax resistance.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.
Patients with chronic lymphocytic leukemia had a significantly reduced antibody response rate when compared with healthy individuals.
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.